Pharma: Clinic Roundup
• Pfizer Inc., of New York, said a Phase IIIb withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary endpoint, defined as the change in mean pain score relative to baseline.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST